RxDoctor Payments Data

Lisa Nguyen

Psychiatric/Mental Health · Aurora, CONPI 1942402425

Payments from drug & device makers

$583in general payments, 2019–2025

Across 9 payments — averaging $64.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$135
  • Otsuka America Pharmaceutical, Inc.$128
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$125
  • AstraZeneca$120
  • Sunovion Pharmaceuticals Inc.$20
  • Pfizer$19
  • plus $36 from 2 others

What the payments were for

  • Food & beverage$57899%
  • Education$51%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$583 in reported general payments places this provider in the 65th percentile of 873 psychiatric/mental health providers in Colorado.

See all psychiatric/mental health providers in Colorado

Medicare billing

Part B allowed, 2024
$29,942
Medicare patients
36
Services billed
329

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate34$108,808
VraylarCariprazine Hcl45$77,236
AristadaAripiprazole Lauroxil26$75,261
Abilify MaintenaAripiprazole15$37,336
Lurasidone Hcl49$13,203
TrintellixVortioxetine Hydrobromide14$7,045
Varenicline Tartrate15$5,363
DayvigoLemborexant13$4,870
Paliperidone ErPaliperidone31$4,277
Gabapentin134$3,563
Trazodone Hcl169$3,096
Quetiapine Fumarate157$3,075
Vilazodone Hcl12$2,221
Olanzapine97$1,814
Duloxetine Hcl101$1,604

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$17$77,23645 claims
Alkermes, Inc.Aristada$19$75,26126 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$128$37,33615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 873 psychiatric/mental health providers in Colorado.

Other psychiatric/mental health in Aurora

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →